Rising Hospital and Drug Costs Are Squeezing U.S. Businesses and Investors
Escalating hospital and pharmaceutical prices are becoming a material burden for American employers, adding pressure to margins, wage planning and benefit budgets at a time when companies are already facing higher operating costs. The issue is moving from a healthcare-policy debate into a broader market concern, with implications for insurers, benefits brokers and publicly traded firms that fund employee coverage.
